<DOC>
	<DOCNO>NCT01230957</DOCNO>
	<brief_summary>This study evaluate ACAM-CDIFF™ vaccine population middle-aged elderly individual risk exposure Clostridium difficile impend hospitalization residence care facility . Primary Objectives : - To describe safety profile subject study group . - To describe immune response elicit toxoid A toxoid B subject study group . Observational Objective : - To describe occurrence first-time Clostridium difficile infection ( CDI ) episodes .</brief_summary>
	<brief_title>Study Different Formulations Clostridium Difficile Toxoid Vaccine Given Three Different Schedules Adults</brief_title>
	<detailed_description>Participants receive 3 dos either one 4 different formulation ACAM-CDIFF™ vaccine placebo , one 3 different schedule . The trial 2 stage . Stage I test 4 different formulation ACAM-CDIFF™ vaccine . Stage II explore different vaccination schedule use one formulation . Participants follow safety immunogenicity ; stool sample also provide case diarrhea .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 40 75 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure For woman childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination At risk develop Clostridium difficile infection trial impend elective surgery hospitalization within 60 day enrollment , current impend residence longterm care facility rehabilitation facility . Known pregnancy , positive urine pregnancy test Currently breastfeed child Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Receipt vaccine 4 week precede first trial vaccination , except influenza ( seasonal pandemic ) pneumococcal vaccine Planned receipt vaccine 4 week follow trial vaccination , except influenza ( seasonal pandemic ) pneumococcal vaccine Previous vaccination Clostridium difficile either trial vaccine another vaccine Current prior Clostridium difficile infection ( CDI ) episode Receipt blood bloodderived product past 3 month , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Selfreported seropositivity Human Immunodeficiency Virus ( HIV ) , hepatitis B , hepatitis C Anticipated current receipt kidney dialysis treatment Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine contain substance Selfreported thrombocytopenia , contraindicate intramuscular ( IM ) vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate IM vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Chronic illness , opinion investigator , stage might interfere trial conduct completion Identified study site employee involve protocol may direct access trialrelated data Subjects history intestinal diverticular bleed Subjects surgery within past three month gastrointestinal ( GI ) malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Clostridium difficile infection</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Pseudomembranous colitis</keyword>
	<keyword>Clostridium Difficile Toxoid Vaccine</keyword>
	<keyword>ACAM-CDIFF™ vaccine</keyword>
</DOC>